Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
NEW YORK, April 13, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational update conference call with the investment community on Friday, April 28, 2017, at 8:30 a.m. Eastern Time.
The conference call will feature remarks by Dr. Lan Huang, Ph.D., Chairman and CEO, and Richard Brand, CFO. The dial-in numbers for the conference call are +1.877.451.6152 (U.S. Toll Free) or +1.201.389.0879 (International). Please ask the operator to join you into the BeyondSpring Call.
A live webcast of the conference call will be available online which can be accessed through the Investor Relations section of BeyondSpring’s website, http://ir.beyondspringpharma.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a replay of the call will be available through May 12, 2017, at +1.844.512.2921 (U.S. Toll Free) or +1.412.317.6671 (International). Participants must use the following code to access the replay of the call: 13659965. Also, a replay of the webcast will remain available on http://ir.beyondspringpharma.com for 30 days following the call.
The Company also plans to issue an operational update press release on Friday, April 28th before the U.S. markets open, which will include its financial results for the year ended December 31, 2016.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Investor Relations: Garth Russell / Allison Soss KCSA Strategic Communications P: +1-212-682-6300 [email protected] / [email protected] Media Relations: Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 [email protected] / [email protected]
